Amneal Pharmaceuticals (NASDAQ:AMRX) reported fourth-quarter and full-year 2025 results and outlined its 2026 outlook, ...
Teva Pharmaceutical Industries (NYSE: TEVA) is an interesting investment story. For the right investor, it could be an attractive buy. For me, however, it isn't. Here's the opportunity that Teva has ...
As one long-running feud over the controversial generic drug carveout known as “skinny” labeling comes to a close, the United States’ top lawyer is urging the Supreme Court to reverse a recent ...
BFA Law is investigating Eos Energy Enterprises, Inc. after its stock plummeted over 39% due to disappointing 2025 financial results and manufacturing issues, potentially violating federal securities ...
BFA Law is investigating Eos Energy Enterprises, Inc. after its stock plummeted over 39% due to disappointing 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results